AI assistant
Phathom Pharmaceuticals, Inc. — Director's Dealing 2022
Sep 2, 2022
32407_dirs_2022-09-02_36689c91-bdd2-4e47-ada9-4becb456aad9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Phathom Pharmaceuticals, Inc. (PHAT)
CIK: 0001783183
Period of Report: 2022-09-01
Reporting Person: Curran Terrie (Director, President and Chief Executive)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-09-01 | Common Stock | A | 7500 | $0.00 | Acquired | 85246 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 2235.9 | Indirect |
Footnotes
F1: Represents restricted stock units ("RSUs") granted on September 1, 2022. Fifty percent (50%) of the total number of RSUs granted vest on each of March 1, 2023 and June 1, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2: Includes 1,151 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2022.
F3: Includes 1,511.80 shares acquired under the Phathom Pharmaceuticals, Inc. 401(k) plan.